Allovir IncNASDAQ:ALVRNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.7549
- TODAY'S CHANGE (%)0.0075 (1.0035%)
- Bid / Lots0.7402/ 98
- Ask / Lots0.7980/ 10
- Open / Previous Close0.7402 / 0.7474
- Day Range
- 52 Week Range
- Volume157,386
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALVR |
|---|---|---|
| 09:32 ET | 366 | 0.7402 |
| 09:41 ET | 4444 | 0.765 |
| 09:45 ET | 100 | 0.7407 |
| 09:48 ET | 200 | 0.76485 |
| 09:54 ET | 300 | 0.76485 |
| 09:57 ET | 100 | 0.7526 |
| 10:03 ET | 100 | 0.7407 |
| 10:08 ET | 100 | 0.7417 |
| 10:10 ET | 100 | 0.76485 |
| 10:12 ET | 1100 | 0.76485 |
| 10:14 ET | 200 | 0.7411 |
| 10:15 ET | 300 | 0.7411 |
| 10:19 ET | 200 | 0.7648 |
| 10:21 ET | 495 | 0.7648 |
| 10:24 ET | 100 | 0.75225 |
| 10:26 ET | 232 | 0.7522 |
| 10:30 ET | 300 | 0.7522 |
| 10:32 ET | 100 | 0.7406 |
| 10:37 ET | 100 | 0.7406 |
| 10:42 ET | 300 | 0.7475 |
| 10:51 ET | 200 | 0.7465 |
| 10:55 ET | 1203 | 0.7406 |
| 10:57 ET | 162 | 0.7413 |
| 11:06 ET | 18721 | 0.7445 |
| 11:08 ET | 2667 | 0.74635 |
| 11:11 ET | 800 | 0.7442 |
| 11:18 ET | 200 | 0.7479 |
| 11:33 ET | 100 | 0.7478 |
| 11:36 ET | 100 | 0.7405 |
| 11:51 ET | 5570 | 0.7479 |
| 11:56 ET | 100 | 0.745 |
| 11:58 ET | 990 | 0.7482 |
| 12:00 ET | 100 | 0.7451 |
| 12:02 ET | 200 | 0.7489 |
| 12:05 ET | 230 | 0.74705 |
| 12:12 ET | 145 | 0.7451 |
| 12:16 ET | 100 | 0.7451 |
| 12:20 ET | 100 | 0.7451 |
| 12:21 ET | 350 | 0.74675 |
| 12:25 ET | 1888 | 0.7467 |
| 12:30 ET | 100 | 0.7467 |
| 12:32 ET | 100 | 0.745 |
| 12:34 ET | 100 | 0.745 |
| 12:36 ET | 2000 | 0.745 |
| 12:38 ET | 703 | 0.7482 |
| 12:39 ET | 200 | 0.7466 |
| 12:41 ET | 300 | 0.745 |
| 12:45 ET | 3200 | 0.75 |
| 12:56 ET | 3420 | 0.764 |
| 12:59 ET | 100 | 0.746 |
| 01:12 ET | 200 | 0.746 |
| 01:14 ET | 100 | 0.7455 |
| 01:15 ET | 100 | 0.7636 |
| 01:19 ET | 100 | 0.7455 |
| 01:21 ET | 100 | 0.7636 |
| 01:26 ET | 464 | 0.7543 |
| 01:28 ET | 300 | 0.745 |
| 01:30 ET | 100 | 0.763 |
| 01:33 ET | 500 | 0.763 |
| 01:37 ET | 300 | 0.7543 |
| 01:39 ET | 200 | 0.751 |
| 01:44 ET | 200 | 0.7505 |
| 01:51 ET | 200 | 0.7505 |
| 01:55 ET | 400 | 0.751 |
| 01:57 ET | 100 | 0.75 |
| 02:00 ET | 100 | 0.75 |
| 02:02 ET | 100 | 0.7565 |
| 02:04 ET | 240 | 0.7565 |
| 02:08 ET | 200 | 0.75 |
| 02:11 ET | 100 | 0.75 |
| 02:13 ET | 721 | 0.7525 |
| 02:15 ET | 100 | 0.7525 |
| 02:18 ET | 100 | 0.75 |
| 02:22 ET | 100 | 0.75225 |
| 02:24 ET | 300 | 0.75 |
| 02:26 ET | 464 | 0.75205 |
| 02:27 ET | 100 | 0.75 |
| 02:29 ET | 100 | 0.7519 |
| 02:31 ET | 300 | 0.75 |
| 02:36 ET | 221 | 0.7501 |
| 02:38 ET | 100 | 0.7519 |
| 02:40 ET | 100 | 0.7519 |
| 02:42 ET | 100 | 0.75 |
| 02:44 ET | 100 | 0.7519 |
| 02:45 ET | 100 | 0.7519 |
| 02:51 ET | 340 | 0.75 |
| 02:56 ET | 243 | 0.75185 |
| 02:58 ET | 100 | 0.75 |
| 03:00 ET | 200 | 0.75 |
| 03:02 ET | 100 | 0.7518 |
| 03:05 ET | 100 | 0.75 |
| 03:12 ET | 317 | 0.75 |
| 03:14 ET | 100 | 0.75 |
| 03:16 ET | 460 | 0.7501 |
| 03:18 ET | 300 | 0.7502 |
| 03:23 ET | 762 | 0.7502 |
| 03:25 ET | 100 | 0.75015 |
| 03:27 ET | 1105 | 0.75005 |
| 03:30 ET | 2952 | 0.75 |
| 03:34 ET | 6936 | 0.7502 |
| 03:36 ET | 1530 | 0.75 |
| 03:38 ET | 1311 | 0.7505 |
| 03:39 ET | 100 | 0.7501 |
| 03:45 ET | 300 | 0.75 |
| 03:48 ET | 100 | 0.75 |
| 03:50 ET | 300 | 0.7501 |
| 03:52 ET | 476 | 0.75 |
| 03:56 ET | 6792 | 0.7508 |
| 03:57 ET | 632 | 0.7516 |
| 03:59 ET | 52467 | 0.7549 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Allovir Inc | 86.0M | -0.5x | --- |
Connect Biopharma Holdings Ltd | 86.2M | -1.7x | --- |
Chimerix Inc | 86.4M | -1.0x | --- |
Entera Bio Ltd | 82.7M | -7.9x | --- |
IO Biotech Inc | 81.7M | -0.6x | --- |
Leap Therapeutics Inc | 90.3M | -1.0x | --- |
Company Information
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.
Contact Information
- Headquarters
- 1100 Winter StreetWALTHAM, MA, United States 02451
- Phone
- 617-433-2605
- Fax
- 302-655-5049
Executives
- Executive Chairman of the Board
- David Hallal
- President, Chief Financial Officer, Director
- Vikas Sinha
- Chief Executive Officer, Director
- Diana Brainard
- Co-Founder, Chief Scientific Officer
- Ann Leen
- Chief Accounting Officer
- Brett Hagen
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $86.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 115.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.77 |
EPS | $-1.65 |
Book Value | $1.28 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
